A $402,500 two-year grant from the Cure Alzheimer’s Fund will support research into a surprising twist in the fight against Alzheimer’s disease: how the brain’s own immune cells, microglia, might inadvertently contribute to the spread of the toxic tau protein that characterizes the condition. The research, led by Dr. Sarah C. Hopp at UT Health San Antonio, aims to unravel the complex role these cells play, potentially opening new avenues for treatment and prevention.
Dr. Hopp, an associate professor of pharmacology with the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases and the South Texas Alzheimer’s Disease Research Center, has been instrumental in uncovering the behavior of microglia. The study, beginning this month, will test the hypothesis that microglia uptake of tau is a key mechanism driving its spread throughout the brain, and that specific molecular pathways determine whether this process protects or harms neurons. Understanding this delicate balance is crucial, as tau tangles are closely linked to cognitive decline and memory loss in Alzheimer’s patients.
The Cure Alzheimer’s Fund, a nonprofit organization dedicated to funding high-impact research, recognized the potential of Dr. Hopp’s work. The organization states its mission is to fund research “with the highest probability of preventing, slowing or reversing Alzheimer’s disease.” CureAlz has consistently supported innovative projects aimed at understanding the underlying mechanisms of this devastating disease, which currently affects millions worldwide.
Microglia are typically considered the brain’s first line of defense, responsible for clearing debris and repairing damage. However, recent evidence suggests a more nuanced role. As detailed in a paper published on the CureAlz website, titled “How Do Microglia Contribute to the Spread of Tau Pathology in Alzheimer’s Disease?”, toxic forms of tau, when “misfolded,” can act as a “lousy influence,” inducing healthy tau proteins to misfold as well, creating a cascading effect that spreads throughout the brain. Microglia, encountering these “toxic seeds” of tau, may inadvertently contribute to the problem by engulfing the misfolded protein and then releasing it, amplifying its harmful effects.
The Microglia Paradox: From Protectors to Spreaders
Dr. Hopp’s team has already identified the cellular machinery that allows microglia to internalize tau and mapped the control points that determine whether the microglia successfully destroy it or release it back into the brain. Their research revealed that only about a quarter of microglia actually absorb the misfolded tau. This suggests a significant degree of variability in microglial function, and understanding the factors that influence this variability is a key focus of the new research.
The team also discovered that this subpopulation of tau-absorbing microglia expresses a unique set of genes related to endocytosis – the process by which cells engulf substances – as well as genes linked to stress within the cell’s recycling centers (lysosomes) and migration. These changes suggest that when microglia ingest too much tau, their ability to properly digest it breaks down, leading to the release of inflammatory signals and potentially the spread of tau instead of its elimination.
Experiments have confirmed this pattern: initially, microglia reduce tau accumulation, but over time, stress within their lysosomes leads them to release “seeds” of tau that can further propagate the pathology. Crucially, the team identified the LRP1 receptor (for low-density lipoprotein receptor-related protein 1) as essential for tau uptake; removing LRP1 significantly reduced the amount of tau internalized by microglia.
Unraveling the Molecular Switches
The new research will focus on three interconnected objectives. First, Dr. Hopp’s team will work to identify what makes some microglia more likely to engulf tau than others. Using advanced gene expression mapping, microglia derived from human stem cells, and post-mortem brain tissue from Alzheimer’s patients, they aim to define a distinct “fingerprint” of these tau-engulfing cells. This will assist reveal the cellular characteristics or environmental signals that drive microglia toward this specialized role.
Second, the team will study how microglia transition from being tau “cleaners” to tau “spreaders.” They will focus on two processes – microglial migration and the lysosomal system – to identify when and how the protective roles of microglia degrade. Understanding this transition could uncover new intervention points to preserve healthy microglial function.
Finally, the researchers will test whether tau absorption via the LRP1 receptor is essential for disease progression. Using mice engineered to lack LRP1 in their microglia, they will determine if blocking this pathway slows or prevents the spread of tau in connected brain regions.
Implications for Future Therapies
The findings from this research could have significant implications for the development of new Alzheimer’s therapies. By identifying the molecular switches that control the microglia’s role in tau propagation, researchers may be able to develop strategies to maintain microglia in their protective mode – eliminating toxic proteins rather than helping them spread. This could involve targeting specific pathways within microglia to enhance their ability to clear tau or preventing them from releasing it in the first place.
The work builds on a growing understanding of the immune system’s complex role in neurodegenerative diseases. Dr. Hopp’s research specifically focuses on the interplay between microglia and tau pathology, a critical area of investigation in the search for effective Alzheimer’s treatments.
The next step in this research will be the initiation of the planned experiments, with initial results expected within the first year of the grant period. Researchers will be closely monitoring the effects of manipulating microglial function in both cell cultures and animal models, providing valuable insights into the dynamics of tau propagation and the potential for therapeutic intervention.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It’s essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have thoughts on this research? Share your comments below, and please consider sharing this article with your network to raise awareness about the ongoing efforts to combat Alzheimer’s disease.
Related reading
